Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebendazole plus mesalamine for ulcerative colitis
IRCT20220115053713N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of mebendazole and Salcrozine in autoimmune colitis and Ulcerative rectosigmoiditis (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Clinical symptoms. Started Apr 2022; status: completed.
02
Drugs
mebendazoleSalcrozine
03
Conditions
autoimmune colitisUlcerative rectosigmoiditis
Beyond the preview
Go deeper on IRCT20220115053713N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220115053713N2.